 |
Prospector
Profile
1112-02
|
| |
| Generex Biotechnology Corp. |
NAICS |
541710 |
| 33 Harbour Square, Suite 202
Toronto, Ontario, Canada M5J 2G2 |
Description |
Biotechnology |
| (416) 364-2551 |
Employees |
25 |
| http://www.generex.com/ |
Revenue |
(mil) |
0.1820 |
| |
Income |
(mil) |
-23.5040 |
| |
Assets |
(mil) |
46.4040 |
| |
Liability |
(mil) |
10.3330 |
| |
(for the year ended 2007-07-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Generex Biotechnology Corp. reported net losses of $23,504,958 for the year ended July 31, 2007, compared to net losses of $67,967,204 and $24,001,735 for the fiscal years ended July 31, 2006 and 2005, respectively. The Company also used cash for operating activities of $17,231,065 for the year ended July 30, 2007, compared to $10,573,416 and $11,400,145 for the years ended July 31, 2006 and 2005, respectively. The Company's balance sheet at July 31, 2007 showed an accumulated deficit of $212,000,270.
|
| |
|
Intellectual Property:
The Company holds a number of patents in the United States and foreign countries covering its buccal and other delivery technologies. It also has developed brand names and trademarks for products in all areas. The Company currently has 20 issued U.S. patents and 2 pending U.S. patent application pertaining to aspects of buccal delivery technology including oral administration of macromolecular formulations as well as pain relief medications such as morphine and fentanyl. The Company currently holds 2 issued Canadian patents and 10 pending Canadian patent applications also relating to aspects of buccal drug delivery technology. It also holds 87 issued patents and 79 pending patent applications covering its drug delivery technology, including over-the-counter glucose and energy spray products and metformin gum. In addition, it has 1 issued Canadian patent, 1 U.S. patent and 1 pending U.S. patent application pertaining to delivery technologies other than buccal delivery technology. It also has an indirect interest in seven drug delivery patents held by Centrum Biotechnologies, Inc. The Company's Antigen subsidiary currently holds 8 issued U.S. patents, 3 Australian patents, 4 other foreign patents, 6 pending U.S. patent applications, 2 pending U.S provisional patents and 28 foreign patent applications concerning technology for modulating the immune system via activation of antigen-specific helper T lymphocytes. In addition to patents, the Company holds intellectual property in the form of trademark applications worldwide on products such as Generex Oral-lyn™. [SEC Filing 10-K 10-15-07]
|
| |
|
Description:
The Company engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
|
| |
|
Officers:
Anna E. Gluskin (Chair, Pres. & CEO); Rose C. Perri (COO, CFO, Sec., Treas. & Dir.); Gerald Bernstein, M.D. (VP & Dir.); Mark Fletcher, Esq. (EVP & Gen. Counsel); John P. Barratt (Dir.); Brian T. McGee (Dir.); Peter G. Amanatides (Dir.); Nola E. Masterson (Dir.)
|
| |
|
Auditor:
Danziger Hochman Partners LLP
|
| |
|
Securities:
Common Stock-Symbol GNBT; NasdaqGM;
109,985,836 common shares outstanding as of October 3, 2007.
|
| |
| |
| |
| return to main page |
|
|
